ArticleHealth security
Assessing the Risks Posed by the Convergence of Artificial Intelligence and Biotechnology.
Article in Health security. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Neuromodulation using Bioelectronics-enabled therapies to combat insulin resistance and its comorbidities.Journal of diabetes and metabolic disorders · 2026Review
- Artificial intelligence in periodontal disease research: a bibliometric and visualized analysis of global research trends (2007-2025).The Saudi dental journal · 2026Review
- Improving governance in the age of synthetic biology, artificial intelligence, and diverging threats.Frontiers in bioengineering and biotechnology · 2026Article
- Strengthening global biosecurity for synthetic nucleic acid technology: from sequence screening to risk-based governance in the AI era.Frontiers in bioengineering and biotechnology · 2026Review
- Article
- The convergence of AI and synthetic biology: the looming deluge.npj biomedical innovations · 2025Article
- The utility of artificial intelligence in visualization of pediatric gastrointestinal mucosa.Frontiers in pediatrics · 2025Review
- Emerging technologies transforming the future of global biosecurity.Frontiers in digital health · 2025Review
- Biosecurity Assessments for Emerging Transdisciplinary Biotechnologies: Revisiting Biodefense in an Age of Synthetic Biology.Applied biosafety : journal of the American Biological Safety Association · 2024Review
- Biosecurity Risk Assessment for the Use of Artificial Intelligence in Synthetic Biology.Applied biosafety : journal of the American Biological Safety Association · 2024Article
- The whack-a-mole governance challenge for AI-enabled synthetic biology: literature review and emerging frameworks.Frontiers in bioengineering and biotechnology · 2024Review
- Expectations for Artificial Intelligence (AI) in Psychiatry.Current psychiatry reports · 2022Review
- Interpretable detection of novel human viruses from genome sequencing data.NAR genomics and bioinformatics · 2021Article
- Ethical Considerations Emerge from Artificial Intelligence (AI) in Biotechnology.Avicenna journal of medical biotechnologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rapid developments are currently taking place in the fields of artificial intelligence (AI) and biotechnology, and applications arising from the convergence of these 2 fields are likely to offer immense opportunities that could greatly benefit human health and biosecurity. The combination of AI and biotechnology could potentially lead to breakthroughs in precision medicine, improved biosurveillance, and discovery of novel medical countermeasures as well as facilitate a more effective public health emergency response. However, as is the case with many preceding transformative technologies, new opportunities often present new risks in parallel. Understanding the current and emerging risks at the intersection of AI and biotechnology is crucial for health security specialists and unlikely to be achieved by examining either field in isolation. Uncertainties multiply as technologies merge, showcasing the need to identify robust assessment frameworks that could adequately analyze the risk landscape emerging at the convergence of these 2 domains.This paper explores the criteria needed to assess risks associated with Artificial intelligence and biotechnology and evaluates 3 previously published risk assessment frameworks. After highlighting their strengths and limitations and applying to relevant Artificial intelligence and biotechnology examples, the authors suggest a hybrid framework with recommendations for future approaches to risk assessment for convergent technologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.